Bevacizumab

贝伐珠单抗

Report date: 2026/04/07 20:00:20
First In Class

Base Information

Drug NameBevacizumab
Drug Alias Name贝伐株单抗Bevacizumabum贝伐赛珠单抗anti-VEGF MAb贝伐单抗 +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Brain metastases +[159] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsBreast Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2004/02/26
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesNavifus CoCancer Center Of Sun Yat Sen UniversityUniversity Medical Center Groningen +[25] 
Inactive CompaniesOhiohealth Research InstituteXoft IncLaboratorios Richmond S.A.C.I.F. +[67] 
Active IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Brain metastases +[41] 
Inactive IndicationsMetastatic breast cancerSkin MelanomaCNS Embryonal Tumor +[118] 

Other Information

ATC CodeL01XC07
Related LinksWikipediaDrugBankKEGG